| Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer (NCT05098210) | Fred Hutchinson Cancer Center | 2022-06-09 |
| Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial (NCT05339022) | Ohio State University Comprehensive Cancer Center | 2022-04-14 |
| Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer (NCT05166616) | City of Hope Medical Center | 2022-03-07 |
| Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer (NCT05136846) | Ohio State University Comprehensive Cancer Center | 2021-12-06 |
| Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer (NCT04751747) | Rutgers, The State University of New Jersey | 2021-02-11 |
| NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer (NCT04505267) | M.D. Anderson Cancer Center | 2021-02-10 |
| Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (NCT04092283) | National Cancer Institute (NCI) | 2020-04-29 |
| Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy (NCT03965689) | National Cancer Institute (NCI) | 2020-04-16 |
| Resiliency Among Older Adults Receiving Lung Cancer Treatment (NCT04229381) | Ohio State University Comprehensive Cancer Center | 2020-01-22 |
| Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial (NCT03801902) | National Cancer Institute (NCI) | 2019-10-28 |
| Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer (NCT04013542) | M.D. Anderson Cancer Center | 2019-09-13 |
| Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced (NCT03225664) | M.D. Anderson Cancer Center | 2018-02-03 |
| Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (NCT03132532) | Mayo Clinic | 2017-07-31 |
| CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer (NCT02955290) | Roswell Park Cancer Institute | 2016-12-22 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (NCT02419495) | M.D. Anderson Cancer Center | 2015-06-26 |